Trials / Completed
CompletedNCT00209339
Feasibility Study of a Percutaneous Mitral Valve Repair System.
A Study of the Evalve Cardiovascular Valve Repair System Endovascular Valve Edge-to-Edge REpair STudy (EVEREST I).
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Abbott Medical Devices · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Prospective, multi-center, Phase I study of the Evalve Cardiovascular Valve Repair System (CVRS) in the treatment of mitral valve regurgitation. Patients will undergo 30-day, 6 month, 12 month, and 5 year clinical follow-up.
Detailed description
Phase I evaluation of the safety and effectiveness of an endovascular approach to the repair of mitral valve regurgitation using the Evalve Cardiovascular Valve Repair System. The study is a prospective, multi-center, Phase I study of the Evalve Cardiovascular Valve Repair System (CVRS) in the treatment of mitral valve regurgitation. A minimum of 20 patients will be enrolled (an additional maximum of 12 roll in-patients, a maximum of 2 per site, may be enrolled and analyzed separately). Patients will undergo 30-day, 6 month and 12 month clinical follow-up. Up to 12 clinical sites throughout the US may participate. The primary endpoint is acute safety at thirty days, with a secondary efficacy endpoint of reduction of MR.
Conditions
- Mitral Valve Insufficiency
- Mitral Valve Regurgitation
- Mitral Valve Incompetence
- Mitral Regurgitation
- Mitral Insufficiency
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Percutaneous mitral valve repair (MitraClip Implant) | Phase I evaluation of the safety and effectiveness of an endovascular approach to the repair of mitral valve regurgitation using the Evalve MitraClip Cardiovascular Valve Repair System. |
Timeline
- Start date
- 2003-07-01
- Primary completion
- 2006-02-01
- Completion
- 2011-10-01
- First posted
- 2005-09-21
- Last updated
- 2018-11-07
- Results posted
- 2016-08-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00209339. Inclusion in this directory is not an endorsement.